These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 29905380)

  • 1. The effect of azacitidine therapy on the M protein of MDS patients with concomitant MGUS.
    Oka S; Ono K; Nohgawa M
    Am J Hematol; 2018 Sep; 93(9):E220-E222. PubMed ID: 29905380
    [No Abstract]   [Full Text] [Related]  

  • 2. Co-occurrence of monoclonal gammopathy and myelodysplasia: a retrospective study of fourteen cases.
    Yoshida Y; Oguma S; Ohno H; Nakabo Y; Katsurada T; Kawahara M; Kawabata H
    Int J Hematol; 2014 Jun; 99(6):721-5. PubMed ID: 24687918
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Concomitant MDS with isolated 5q deletion and MGUS: case report and review of molecular aspects.
    Nolte F; Mossner M; Jann JC; Nowak D; Boch T; Müller NZ; Hofmann WK; Metzgeroth G
    Eur J Haematol; 2017 Mar; 98(3):302-310. PubMed ID: 27862375
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Addition of Rice Bran Arabinoxylan to Curcumin Therapy May Be of Benefit to Patients With Early-Stage B-Cell Lymphoid Malignancies (Monoclonal Gammopathy of Undetermined Significance, Smoldering Multiple Myeloma, or Stage 0/1 Chronic Lymphocytic Leukemia): A Preliminary Clinical Study.
    Golombick T; Diamond TH; Manoharan A; Ramakrishna R
    Integr Cancer Ther; 2016 Jun; 15(2):183-9. PubMed ID: 27154182
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Successful treatment with azacitidine for myelodysplastic syndrome with large vessel vasculitis].
    Mishima M; Makita M; Sando Y; Yamamoto Y; Shiote Y; Hara Y; Yamamoto K; Imajo K
    Rinsho Ketsueki; 2015 Jan; 56(1):35-7. PubMed ID: 25745966
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Long-Term Follow-up of Monoclonal Gammopathy of Undetermined Significance.
    Kyle RA; Larson DR; Therneau TM; Dispenzieri A; Kumar S; Cerhan JR; Rajkumar SV
    N Engl J Med; 2018 Jan; 378(3):241-249. PubMed ID: 29342381
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Secondary Pulmonary Alveolar Proteinosis Following Treatment with Azacitidine for Myelodysplastic Syndrome.
    Hashimoto M; Itonaga H; Nannya Y; Taniguchi H; Fukuda Y; Furumoto T; Fujioka M; Kasai S; Taguchi M; Taniguchi H; Sato S; Sawayama Y; Atogami S; Iwasaki K; Hata T; Soda H; Moriuchi Y; Nakata K; Ogawa S; Miyazaki Y
    Intern Med; 2020 Apr; 59(8):1081-1086. PubMed ID: 31875636
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Monoclonal gammopathy of undetermined significance and smoldering multiple myeloma.
    Kyle RA; San-Miguel JF; Mateos MV; Rajkumar SV
    Hematol Oncol Clin North Am; 2014 Oct; 28(5):775-90. PubMed ID: 25212882
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Long-term follow-up of patients with monoclonal gammopathy of undetermined significance after kidney transplantation.
    Naina HV; Harris S; Dispenzieri A; Cosio FG; Habermann TM; Stegall MD; Dean PG; Prieto M; Kyle RA; Rajkumar SV; Leung N
    Am J Nephrol; 2012; 35(4):365-71. PubMed ID: 22473253
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Treatment with 5-Azacytidine improves clinical outcome in high-risk MDS patients in the 'real life' setting: A single center observational study.
    Papageorgiou SG; Vasilatou D; Kontos CK; Foukas P; Kefala M; Ioannidou ED; Bouchla A; Bazani E; Dimitriadis G; Pappa V
    Hematology; 2016 Jan; 21(1):34-41. PubMed ID: 26218077
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Unidentified Inflammatory Disease Induced by Azacitidine Therapy for Myelodysplastic Syndrome].
    Inagaki S; Tamai Y; Yoshizawa M; Sato S; Kanbe E; Tanaka E
    Gan To Kagaku Ryoho; 2015 Nov; 42(11):1443-6. PubMed ID: 26602409
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Late hematological improvement of myelodysplastic syndrome following treatment with 5-azacitidine therapy.
    Takaoka K; Hangaishi A; Ito A; Morioka T; Kida M; Usuki K
    Intern Med; 2014; 53(19):2241-3. PubMed ID: 25274238
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A new prognostic index to make short-term prognoses in MDS patients treated with azacitidine: A combination of p53 expression and cytogenetics.
    Nishiwaki S; Ito M; Watarai R; Okuno S; Harada Y; Yamamoto S; Suzuki K; Kurahashi S; Iwasaki T; Sugiura I
    Leuk Res; 2016 Feb; 41():21-6. PubMed ID: 26651421
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Are neurological complications of monoclonal gammopathy of undetermined significance underestimated?
    Steiner N; Schwärzler A; Göbel G; Löscher W; Wanschitz J; Gunsilius E
    Oncotarget; 2017 Jan; 8(3):5081-5091. PubMed ID: 27974705
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Myelodysplastic syndrome with neutrophilic dermatosis successfully treated with azacitidine].
    Kudo D; Shimizu M; Kuroda A; Suyama T; Shinagawa A; Ito S
    Rinsho Ketsueki; 2017; 58(6):607-612. PubMed ID: 28679990
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Cost-effectiveness analysis of azacitidine for myelodysplastic syndromes in Japan].
    Tomonaga M; Kamae I
    Rinsho Ketsueki; 2012 Mar; 53(3):310-7. PubMed ID: 22499047
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Diagnosis, risk stratification and management of monoclonal gammopathy of undetermined significance and smoldering multiple myeloma.
    van de Donk NW; Mutis T; Poddighe PJ; Lokhorst HM; Zweegman S
    Int J Lab Hematol; 2016 May; 38 Suppl 1():110-22. PubMed ID: 27161311
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Selinexor synergizes with azacitidine to eliminate myelodysplastic syndrome cells through p53 nuclear accumulation.
    Guo Y; Liu Z; Duan L; Shen H; Ding K; Fu R
    Invest New Drugs; 2022 Aug; 40(4):738-746. PubMed ID: 35576022
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Long-term follow-up of 241 patients with monoclonal gammopathy of undetermined significance: the original Mayo Clinic series 25 years later.
    Kyle RA; Therneau TM; Rajkumar SV; Larson DR; Plevak MF; Melton LJ
    Mayo Clin Proc; 2004 Jul; 79(7):859-66. PubMed ID: 15244381
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Arterial and venous thrombosis in patients with monoclonal gammopathy of undetermined significance: incidence and risk factors in a cohort of 1491 patients.
    Za T; De Stefano V; Rossi E; Petrucci MT; Andriani A; Annino L; Cimino G; Caravita T; Pisani F; Ciminello A; Torelli F; Villivà N; Bongarzoni V; Rago A; Betti S; Levi A; Felici S; Gentilini F; Calabrese E; Leone G;
    Br J Haematol; 2013 Mar; 160(5):673-9. PubMed ID: 23240810
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.